ABBV:NYE-AbbVie Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 107.74

Change

0.00 (0.00)%

Market Cap

USD 190.26B

Volume

9.25M

Average Target Price

USD 124.08 (+15.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-27 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

N/A

USD416.54B 28.76 18.05
LLY Eli Lilly and Company

N/A

USD196.37B 30.18 30.89
NVS Novartis AG

N/A

USD194.92B 24.41 13.01
PFE Pfizer Inc

N/A

USD186.15B 19.62 19.27
MRK Merck & Co., Inc

N/A

USD183.73B 26.12 24.78
BMY Bristol-Myers Squibb Company

N/A

USD137.41B 93.81 35.02
GSK GlaxoSmithKline plc

N/A

USD83.91B 33.88 13.67
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing ABBV

Symbol Name Weight Mer Price(Change) Market Cap
AGGY WisdomTree Yield Enhanced.. 0.00 % 0.12 %

N/A

USD1.20B
UC76:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.25 %

N/A

USD1.09B
WHEA:LSE SPDR MSCI World Health Ca.. 0.00 % 0.30 %

N/A

USD0.33B
UQLT:LSE UBS (Irl) ETF plc - Facto.. 0.00 % 0.35 %

N/A

N/A
UDVD:LSE SPDR S&P US Dividend Aris.. 0.00 % 0.35 %

N/A

USD2.77B
UC97:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.20 %

N/A

N/A
UC86:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
UC85:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

N/A
UC84:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.00 %

N/A

N/A
UC82:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

N/A
UC81:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

N/A

USD0.19B
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

N/A

USD0.50B
GEND:LSE Lyxor Global Gender Equal.. 0.00 % 0.35 %

N/A

USD0.02B
QDIV:LSE iShares MSCI USA Quality .. 0.00 % 0.35 %

N/A

USD0.28B
IWVU:LSE iShares Edge MSCI World V.. 0.00 % 0.30 %

N/A

USD3.52B
IWVL:LSE iShares Edge MSCI World V.. 0.00 % 0.30 %

N/A

USD3.52B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.17B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.35 %

N/A

N/A
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

N/A

USD0.77B
SUSD:LSE SPDR Bloomberg Barclays 0.. 0.00 % 0.20 %

N/A

USD0.06B
PHE-B:CA Purpose Tactical Hedged E.. 0.00 % 0.97 %

N/A

N/A
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
XDWH:XETRA Xtrackers MSCI World Heal.. 0.00 % 0.25 %

N/A

USD1.09B
WTEU:XETRA WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
WTDY:XETRA WisdomTree US Equity Inco.. 0.00 % 0.35 %

N/A

N/A
WTD9:XETRA WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
VDIV:XETRA VanEck Vectors™ Morning.. 0.00 % 0.00 %

N/A

N/A
UEF9:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
UEF8:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

N/A
UEF0:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

N/A
UBUX:XETRA UBS (Irl) ETF plc - Facto.. 0.00 % 0.35 %

N/A

N/A
UBUT:XETRA UBS (Irl) ETF plc - Facto.. 0.00 % 0.25 %

N/A

N/A
SYBR:XETRA SPDR Bloomberg Barclays 1.. 0.00 % 0.12 %

N/A

USD0.10B
IS3S:XETRA iShares Edge MSCI World V.. 0.00 % 0.30 %

N/A

USD3.52B
IS3S:F iShares Edge MSCI World V.. 0.00 % 0.30 %

N/A

USD3.52B
XDWH:F Xtrackers MSCI World Heal.. 0.00 % 0.25 %

N/A

USD1.09B
WTEU:F WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
WTDY:F WisdomTree US Equity Inco.. 0.00 % 0.35 %

N/A

N/A
WTD9:F WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

N/A
UEF9:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
UEF7:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
UEF0:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

N/A
UBUX:F UBS (Irl) ETF plc - Facto.. 0.00 % 0.35 %

N/A

N/A
UBUT:F UBS (Irl) ETF plc - Facto.. 0.00 % 0.25 %

N/A

N/A
SYBR:F SPDR Bloomberg Barclays 1.. 0.00 % 0.12 %

N/A

USD0.10B
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
BSUS:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.25 %

N/A

N/A
ZWH-U:CA BMO US High Dividend Cove.. 0.00 % 0.65 %

N/A

N/A
BSCP Invesco BulletShares 2025.. 0.00 % 0.10 %

N/A

USD0.87B
IBDN iShares iBonds Dec 2022 T.. 0.00 % 0.10 %

N/A

USD1.42B
ROUS Hartford Multifactor US E.. 0.00 % 0.19 %

N/A

USD0.26B
RDIV Invesco S&P Ultra Dividen.. 0.00 % 0.39 %

N/A

USD0.74B
PPH VanEck Vectors Pharmaceut.. 0.00 % 0.35 %

N/A

USD0.24B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.35B
PHE:CA Purpose Tactical Hedged E.. 0.00 % 1.01 %

N/A

USD0.01B
LQD iShares iBoxx $ Investmen.. 0.00 % 0.14 %

N/A

USD55.24B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

N/A

USD0.05B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

N/A

USD0.05B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

USD2.51B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

N/A

USD2.48B
IBDQ iShares iBonds Dec 2025 T.. 0.00 % 0.10 %

N/A

USD0.95B
IBDL iShares iBonds Dec 2020 T.. 0.00 % 0.10 %

N/A

USD0.95B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.54M
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

N/A

USD2.46B
FDRR Fidelity Dividend ETF for.. 0.00 % 0.29 %

N/A

USD0.31B
FDL First Trust Morningstar D.. 0.00 % 0.45 %

N/A

USD1.39B
ESGW Columbia Sustainable Glob.. 0.00 % 0.40 %

N/A

USD0.01B
DIVA AGFiQ Hedged Dividend Inc.. 0.00 % 1.21 %

N/A

USD3.30M
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

N/A

USD0.76B
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

N/A

USD0.06B
CURE Direxion Daily Healthcare.. 0.00 % 1.08 %

N/A

USD0.14B
CUD:CA iShares US Dividend Growe.. 0.00 % 0.60 %

N/A

USD0.32B
CDC VictoryShares US EQ Incom.. 0.00 % 0.37 %

N/A

USD0.65B
CATH Global X S&P 500 Catholic.. 0.00 % 0.29 %

N/A

USD0.45B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.54M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD0.12B
ZDY-U:CA BMO US Dividend ETF (USD) 0.00 % 0.30 %

N/A

N/A
WBIY WBI Power Factor High Div.. 0.00 % 0.70 %

N/A

USD0.04B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

N/A

N/A
TPLC Timothy Plan US Large/Mid.. 0.00 % 0.52 %

N/A

USD0.16B
TPHD Timothy Plan High Dividen.. 0.00 % 0.52 %

N/A

USD0.12B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.04B
AWTM Aware Ultra-Short Duratio.. 0.00 % 0.23 %

N/A

USD0.22B
IGIB iShares 5-10 Year Investm.. 0.00 % 0.06 %

N/A

USD11.18B
VSMV VictoryShares US Multi-Fa.. 0.00 % 0.35 %

N/A

USD0.15B
PY Principal Value ETF 0.00 % 0.15 %

N/A

USD0.02B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD0.02B
CDL VictoryShares US Large Ca.. 0.00 % 0.35 %

N/A

USD0.19B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

N/A

USD0.19B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

N/A

USD0.01B
SDY SPDR S&P Dividend ETF 0.00 % 0.35 %

N/A

USD17.13B
CAPS:CA Evolve Active US Core Equ.. 0.00 % 0.70 %

N/A

USD3.62M
HID:CA WisdomTree U.S. High Divi.. 0.00 % 0.40 %

N/A

USD4.31M
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

N/A

USD0.33B
ZWH:CA BMO US High Dividend Cove.. 0.00 % 0.65 %

N/A

USD0.75B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.51B
ZDY:CA BMO US Dividend ETF (CAD) 0.00 % 0.30 %

N/A

USD1.33B
XRLV Invesco S&P 500 ex-Rate S.. 0.00 % 0.25 %

N/A

USD0.05B
XLV Health Care Select Sector.. 0.00 % 0.12 %

N/A

USD25.66B
XHC:CA iShares Global Healthcare.. 0.00 % 0.63 %

N/A

USD0.43B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

USD16.10B
SDYL UBS ETRACS Monthly Pay 2x.. 0.00 % 0.30 %

N/A

USD9.68M
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.12 %

N/A

USD0.50B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.55% 75% C 38% F
Dividend Return 1.21% 80% B- 65% D
Total Return 1.76% 88% B+ 44% F
Trailing 12 Months  
Capital Gain 25.70% 88% B+ 64% D
Dividend Return 5.65% 100% A+ 80% B-
Total Return 31.35% 88% B+ 68% D+
Trailing 5 Years  
Capital Gain 97.29% 88% B+ 76% C
Dividend Return 31.09% 100% A+ 81% B-
Total Return 128.38% 88% B+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 14.66% 88% B+ 84% B
Dividend Return 4.23% 88% B+ 80% B-
Total Return 18.89% 88% B+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 29.31% 13% F 23% F
Risk Adjusted Return 64.44% 50% F 74% C
Market Capitalization 190.26B 63% D 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.61 25% F 20% F
Price/Book Ratio 14.49 25% F 7% F
Price / Cash Flow Ratio 10.82 75% C 40% F
EV/EBITDA 21.68 50% F 30% F
Management Effectiveness  
Return on Equity 187.70% 100% A+ 99% A+
Return on Invested Capital 15.96% 63% D 88% B+
Return on Assets 8.19% 75% C 92% A-
Debt to Equity Ratio 593.10% 13% F 4% F
Technical Ratios  
Short Ratio 1.85 38% F 51% F
Short Percent 0.81% 67% D+ 86% B
Beta 0.81 13% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.